fbpx Skip to main content

FRIDAY, Sept. 25, 2020 (HealthDay News) — For patients with type 2 diabetes, once-weekly insulin icodec has glucose-lowering efficacy comparable to once-daily insulin glargine, according to a study published online Sept. 22 in the New England Journal of Medicine to coincide with the European Association for the Study of Diabetes, held virtually from Sept. 21 to 25.

Julio Rosenstock, M.D., from the Dallas Diabetes Research Center, and colleagues conducted a 26-week phase 2 trial to examine the efficacy and safety of once-weekly insulin icodec versus once-daily insulin glargine U100 in 247 patients who had not previously received insulin and whose type 2 diabetes was inadequately controlled with oral medication.

The researchers found that the estimated mean change from baseline was −1.33 and −1.15 percentage points in the glycated hemoglobin levels in the icodec and glargine groups, respectively, to estimated means of 6.69 and 6.87 percent at week 26, with an estimated between-group difference of −0.18 percentage points (95 percent confidence interval, −0.38 to 0.02; P = 0.08). There were low observed rates of hypoglycemia with severity of levels 2 or 3 (0.53 versus 0.46 events per patient-year for the icodec versus glargine group; estimated rate ratio, 1.09; 95 percent confidence interval, 0.45 to 2.65). No between-group difference was observed in insulin-related key adverse events.

“The findings in the present trial suggest that once-weekly insulin has the potential to facilitate insulin management, providing clinical benefits and reducing the number of injections per year from 365 to 52,” the authors write.

The study was funded by Novo Nordisk, the manufacturer of insulin icodec.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Female Physicians Spend More Time in EHR Than Males

More Information

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More